Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 7/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25245928 | 0.99 | PDE3B (0.43) | PDE3BPDE3AP2RY12PDE2ACNR2 | |
| SCHEMBL24675248 | 0.88 | PDE3B (0.40) | PDE3BPDE3AP2RY12RARARARB | |
| SCHEMBL25822816 | 0.85 | PDE3B (0.42) | PDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL29822786 | 0.85 | PDE3B (0.42) | PDE3BPDE3AP2RY12PDE2A | |
| SCHEMBL25824077 | 0.84 | PDE3B (0.41) | PDE3BPDE3AP2RY12PDE2ACNR2 | |
| SCHEMBL24675836 | 0.82 | PDE3B (0.43) | PDE3BPDE3AP2RY12PDE2ACNR2 | |
| SCHEMBL24675839 | 0.82 | PDE3B (0.43) | PDE3BPDE3AP2RY12PDE2ACNR2 | |
| SCHEMBL24675515 | 0.82 | PDE3B (0.43) | PDE3BPDE3AP2RY12PDE2ACNR2 | |
| SCHEMBL24675514 | 0.81 | CA12 (0.41) | PDE3BPDE3AP2RY12PDE2ACNR2 | |
| SCHEMBL29822802 | 0.81 | CA12 (0.41) | PDE3BPDE3AP2RY12PDE2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023129564-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |